Michelle Georgiana Brown

Dr. Michelle Georgiana Brown


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2015 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
IVIvan E. Vickers
Ivan E. Vickers
KHKevin M. Harvey
Kevin M. Harvey
MBMichelle Georgiana Brown
Michelle Georgiana Brown
KNKereann Nelson
Kereann Nelson
MDMarion Bullock DuCasse
Marion Bullock DuCasse
JLJohn Lindo
John Lindo
Dengue is an important mosquito-borne viral infection that affects millions of persons worldwide. Early diagnosis is necessary to effect appropriate management and decrease mortality. Immunochromatographic tests are advantageous in producing dengue test results within 30 min but these results should be sensitive and specific. In this study we evaluated the diagnostic performance of the SD BIOLINE Dengue DUO® rapid immunochromatographic test kit. A panel of 309 dengue and 30 non-dengue single serum samples characterized by using reference enzyme-linked immunosorbent assays (ELISAs) was used. These samples were received in the virology laboratory for routine testing during a dengue type 1 outbreak between October to December, 2012. The overall diagnostic sensitivities of the SD BIOLINE Dengue DUO® rapid testfor IgM, IgG and NSI were 49.3 % (95 % CI: 41.3-57.4), 39.1 % (95 % CI: 33.3-45.2) and 90 % (95 % CI: 82.1-94.7), respectively. The IgM and IgG detection rates were significantly lower than that of the NSI (p < 0.001). However the combination of the IgM detection with NS1 detection or both NS1 and IgG resulted in a significant (p < 0.001) increase in sensitivity to 97.5 % (95 % CI: 92.9-99.2) and 98.9 % (95 % CI: 96.0-99.7), respectively. These higher sensitivities were achieved without any decrease in specificities. This study revealed that combining two or more parameters of the SD BIOLINE Dengue DUO® rapid kit significantly improved the sensitivity of diagnosis of dengue virus infection and supports its usefulness in the Jamaican setting.

1 March 2011
Verified
Journal Article
Closed access
MBMichelle Georgiana Brown
Michelle Georgiana Brown
RSR A Salas
R A Salas
IVI E Vickers
I E Vickers
OHO D Heslop
O D Heslop
MSM F Smikle
M F Smikle

1 March 2011
Verified
Journal Article
Closed access
MBMichelle Georgiana Brown
Michelle Georgiana Brown
RSR A Salas
R A Salas
IVI E Vickers
I E Vickers
OHO D Heslop
O D Heslop
MSM F Smikle
M F Smikle

1 March 2011
Verified
Journal Article
Closed access
MBMichelle Georgiana Brown
Michelle Georgiana Brown
RSR A Salas
R A Salas
IVI E Vickers
I E Vickers
OHO D Heslop
O D Heslop
MSM F Smikle
M F Smikle

Verified
Journal Article
Open access
PDF file
MBMichelle Georgiana Brown
Michelle Georgiana Brown
JLJohn Lindo
John Lindo
IVIvan Vickers
Ivan Vickers
KNKereann Nelson
Kereann Nelson
YPYakima Phillips
Yakima Phillips
ATAndrew Henry Talal
Andrew Henry Talal
Hepatitis C (HCV) continues to present a global public health challenge, with no vaccine available for prevention. Despite the availability of direct-acting antivirals (DAAs) to cure HCV, it remains prevalent in many regions including the Caribbean. As efforts are made to eliminate HCV from the region, existing barriers, such as the high cost of DAAs and lack of an established database of HCV cases within the Caribbean, must be addressed. This review seeks to assess epidemiologic trends (seroprevalence and genotypic diversity) of HCV in the Caribbean and identify gaps in surveillance of the disease. The literature for the period 1 January 2005 to October 2022 was reviewed to gather country-specific data on HCV across the Caribbean. References were identified through indexed journals accessed through established databases using the following keywords: Caribbean, genotype distribution, and general epidemiologic characteristics. The usage pattern of HCV drugs was determined from information obtained from pharmacists across the Caribbean including Jamaica. The prevalence of HCV in the Caribbean was 1.5%; the region should therefore be considered an area of moderate HCV prevalence. The prevalence of HCV among intravenous drug users (21.9–58.8%), persons living with HIV/AIDS (0.8 to 58.5%), prisoners (32.8–64%), and men who have sex with men (MSM) (0.8–6.9%) was generally higher than in the general population (0.8–2.3%). Genotype 1 (83%) was most prevalent followed by genotypes 2 (7.2%) and 3 (2.1%), respectively. Less than 50% of countries in the Caribbean have reliable or well-curated surveillance data on HCV. Drugs currently being used for treatment of HCV infections across the Caribbean include Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir). Some of these drugs are only available in the private sector and are sourced externally whenever needed. While trends point to a potentially higher prevalence of HCV, it will require well-designed random surveys to obtain better estimates of the infection seroprevalence, supported by strong public health laboratory systems. DAAs that are pan-genotypic should translate into treatments that are affordable, accessible, and available to improve cure rates and reduce the HCV burden in the population.

1 September 1999
Verified
Journal Article
Closed access
SWS H Wynter
S H Wynter
COC R O'Gilvie
C R O'Gilvie
CKC Khan
C Khan
MBMichelle Georgiana Brown
Michelle Georgiana Brown
JLJ F Lindo
J F Lindo
SKS D King
S D King